{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:08Z","timestamp":1792787888909,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Visual response to anti-vascular endothelial growth factor (anti-VEGF) therapy in macular edema secondary to retinal vein occlusion (RVO-ME) varies among patients, and baseline predictors remain incompletely defined. This study investigated baseline predictors of visual response and treatment burden after anti-VEGF therapy in eyes with RVO-ME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included 80 eyes from 80 patients with RVO-ME treated at a single center. Baseline clinical characteristics, optical coherence tomography (OCT) biomarkers, and hematologic inflammatory indices were collected. Decimal visual acuity was converted to approximate Early Treatment Diabetic Retinopathy Study (ETDRS) letter scores. Poor functional response was defined as a gain of \u226410 ETDRS letters at 1\u202fmonth after the third anti-VEGF injection. A composite endpoint was used for sensitivity analysis. Treatment burden was assessed by the number of injections within 6\u202fmonths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean baseline and final ETDRS letter scores were 37.46 and 58.93, respectively, with a mean gain of 21.47 letters. Poor functional response occurred in 21 eyes (26.3%). After excluding sparse HRVO cases from regression modeling, CRVO was associated with poor functional response compared with BRVO (OR 6.81, 95% CI 1.17\u201339.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.033), as were higher baseline ETDRS letter score per 10-letter increase (OR 1.85, 95% CI 1.20\u20132.84,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.005) and male sex (OR 5.46, 95% CI 1.34\u201322.35,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.018). Poor response was less frequent among patients with hypertension (OR 0.13, 95% CI 0.03\u20130.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.008). Firth penalized logistic regression yielded similar results. In the continuous outcome model, CRVO was associated with lower final ETDRS letter score (\u03b2\u202f=\u202f\u221213.78 letters, 95% CI \u221219.62 to \u22127.93,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). Conventional qualitative OCT biomarkers were not significantly associated with the primary gain-based endpoint, although CST showed stronger relevance in the composite endpoint analysis. In adjusted Poisson regression, CRVO showed a non-significant trend toward higher injection count.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this small retrospective RVO-ME cohort treated with ranibizumab, CRVO was consistently associated with poorer short-term visual outcome. The association between baseline visual acuity and gain-based response appeared to be influenced by a ceiling effect. Conventional qualitative OCT biomarkers and hematologic inflammatory indices showed limited but potentially complementary value, and treatment-burden findings should be interpreted as exploratory.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1856268","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:28:25Z","timestamp":1781065705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion"],"prefix":"10.3389","volume":"13","author":[{"given":"Xudong","family":"Li","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Wuhan Aier Eye Hanyang Hospital","place":["Wuhan, China"]},{"name":"Aier Eye Hospital Group Co., Ltd.","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Wuhan Aier Eye Hanyang Hospital","place":["Wuhan, China"]},{"name":"Aier Eye Hospital Group Co., Ltd.","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Wuhan Aier Eye Hanyang Hospital","place":["Wuhan, China"]},{"name":"Aier Eye Hospital Group Co., Ltd.","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Wuhan Aier Eye Hanyang Hospital","place":["Wuhan, China"]},{"name":"Aier Eye Hospital Group Co., Ltd.","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/biomedicines13010105","article-title":"The diagnosis and treatment of branch retinal vein occlusions: an update","volume":"13","author":"Darabu\u015f","year":"2025","journal-title":"Biomedicine"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","article-title":"Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: a systematic review and network meta-analysis of randomized controlled trials","volume":"70","author":"Chen","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2147\/OPTH.S110793","article-title":"Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion","volume":"10","author":"Fujihara-Mino","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/2474126420906395","article-title":"Current best clinical practices-Management of Retinal Vein Occlusion","volume":"4","author":"Modi","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41433-025-04089-2","article-title":"Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study","volume":"40","author":"Dinah","year":"2026","journal-title":"Eye"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","article-title":"Longer-term anti-VEGF therapy outcomes in Neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: clinical outcomes in 130 247 eyes","volume":"6","author":"Ciulla","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.survophthal.2025.08.016","article-title":"Predicting treatment response in retinal vein occlusions using baseline optical coherence tomography biomarkers: a systematic review","volume":"71","author":"Hatamnejad","year":"2026","journal-title":"Surv Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1111\/aos.17574","article-title":"SD-OCT-based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti-VEGF therapy","volume":"104","author":"Tsang","year":"2026","journal-title":"Acta Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.18502\/jovr.v19i3.13531","article-title":"Predictive factors for functional and anatomical outcomes after anti-VEGF treatment for macular edema in patients with branch retinal vein occlusion","volume":"19","author":"Cunha Ferreira","year":"2024","journal-title":"J Ophthalmic Vis Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.18240\/ijo.2025.10.13","article-title":"Correlations between inflammatory biomarkers in peripheral blood and branch retinal vein occlusion","volume":"18","author":"Lai","year":"2025","journal-title":"Int J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s12886-025-04483-0","article-title":"Is the C reactive protein\/albumin ratio a good tool for retinal vein occlusion?","volume":"25","author":"Vural","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1761324","DOI":"10.3389\/fmed.2026.1761324","article-title":"Comparative value of retinal structural features versus systemic inflammatory and renal indicators in predicting short-term anti-VEGF response in diabetic macular edema: focus on OCT biomarkers","volume":"13","author":"Li","year":"2026","journal-title":"Front Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41433-023-02488-x","article-title":"Outcomes in patients with retinal vein occlusion with good baseline visual acuity","volume":"37","author":"Liu","year":"2023","journal-title":"Eye (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40123-022-00511-0","article-title":"Complete blood count-derived inflammation indices and retinal vein occlusion: a case\u2013control study","volume":"11","author":"Kazantzis","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000550350","article-title":"Predictive value of optical coherence tomography biomarkers on visual outcomes in patients with retinal vein occlusion","volume":"249","author":"Bouchikh-El Jarroudi","year":"2026","journal-title":"Ophthalmologica"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3390\/biomedicines13061308","article-title":"Predictive role of complete blood count-derived inflammation indices and optical coherence tomography biomarkers for early response to intravitreal anti-VEGF in diabetic macular edema","volume":"13","author":"Ergin","year":"2025","journal-title":"Biomedicine"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.6026\/973206300212781","article-title":"Inflammatory and hematologic biomarker profiles across central branch and hemi-retinal vein occlusion","volume":"21","author":"Kushwaha","year":"2025","journal-title":"Bioinformation"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1856268\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:28:29Z","timestamp":1781065709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1856268\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":18,"alternative-id":["10.3389\/fmed.2026.1856268"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1856268","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1856268"}}